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Chromosomal common fragile sites (CFSs) are speciﬁc mammalian genomic regions that show an increased frequency of gaps and
breaks when cells are exposed to replication stress in vitro. CFSs are also consistently involved in chromosomal abnormalities in
vivo related to cancer. Interestingly, several CFSs contain one or more tumor suppressor genes whose structure and function are
often aﬀected by chromosomal fragility. The two most active fragile sites in the human genome are FRA3B and FRA16D where
the tumor suppressor genes FHIT and WWOX are located, respectively. The best approach to study tumorigenic eﬀects of altered
tumorsuppressorslocatedatCFSsinvivoistogeneratemousemodelsinwhichthesegenesareinactivated.Thispapersummarizes
our present knowledge on mouse models of cancer generated by knocking out tumor suppressors of CFS.
1.Introduction
Fragile sites can be deﬁned as heritable-speciﬁc loci on
human chromosomes that exhibit nonrandom gaps or
breaks when chromosomes are exposed to speciﬁc cell
culture conditions [1]. Classiﬁcation of fragile sites as rare
or common depends on their expression frequency within
the population [2]. Rare fragile sites are identiﬁable in less
than 5% of the population, while common fragile sites are an
intrinsic part of the regular structure of the chromosomes
that are present in all individuals [1]. Fragile sites are
often involved in deletions and translocations [3], in sister
chromatid exchanges [4], in plasmid integration [5], and
in intrachromosomal gene ampliﬁcation [6]. Interestingly,
some fragile sites, especially common sites, are involved
in chromosomal tumor-related rearrangements, such as the
deletions[7]andtranslocations[8]foundinvarioustumors.
The cytogenetic expression of common fragile sites is visible
over wide chromosomal regions of mega-bases in size [1].
These sites seem therefore to represent regions of fragility,
rather than speciﬁc loci [9]. The importance of common
fragile sites in cancer is particularly relevant when one or
more tumor suppressor genes are located within a speciﬁc
region of fragility. For instance, FRA3B,the mostactivecom-
mon fragile site on human metaphase chromosomes, maps
to a region on chromosome 3p14.2 associated with deletions
or translocation breakpoints in a vast number of human
cancers, including lung [10], breast [11], esophagus [12],
pancreas [13], and kidney [14]. The FHIT (Fragile HIstidine
Triad) gene maps to the same chromosomal region ofFRA3B
[15]. It has been shown that this gene is frequently deleted
[11, 15, 16] or involved in translocation breakpoints [15, 17]
in a large number of tumor types. Other common fragile
sites have been implicated in homozygous deletions or loss
of heterozygosity (LOH) observed in various malignancies
[1]: FRA16D, located on chromosome 16q23.2 and altered
in breast [18], prostate [19], and hepatocellular carcinoma
[20]; FRA6E on 6q26 [21], and FRA7G on 7q31.2 [22], both
altered in ovarian cancer among others. The WWOX tumor
suppressor gene, in the FRA16D region, the second most2 Journal of Biomedicine and Biotechnology
Table 1: Synopsis of CFS tumor suppressor genes and their mouse models of cancer.
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Table 1: Continued.
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active common fragile site in the human genome [23], has
been cloned [24]. The involvement of WWOX in cancer has
been reviewed recently by Del Mare et al. [25].
An important step in the functional characterization
and validation of putative human tumor suppressor genes
is the generation of recombinant mouse knockout models
with both alleles of the gene of interest inactivated. Genes
associated to well-characterized human CFSs are conserved
in the mouse genome, but the level of fragility of CFSs may
not be the same. In this paper we describe recombinant
mouse strains carrying inactivated fragile site tumor sup-
pressor genes, the fragile genes that have been most exten-
sively examined for association with cancer development
(Table 1).
2.FHIT
T h er o l eo fFHIT as a tumor suppressor, its biochem-
istry, genetics, pathology, and biology, has been extensively
reviewed since the discovery of the gene, 14 years ago
(e.g., [26–28]). Previously, we summarized the insights that
had emerged until 2004 into the genetics and biology of
FHIT-deﬁcient mice with particular focus on carcinogenesis
and gene delivery studies [29]. New developments since 2004
concerning the FHIT gene and gene product are reviewed in
this section.
Although the usefulness of a model like FHIT-deﬁcient
mouse rests mainly in the possibility to perform in vivo
experiments, normal cells from diﬀerent tissues with a
deﬁned FHIT genotype can also be isolated, cultured, and
studied for speciﬁc purposes. For example, we established
normal kidney cell lines from FHIT+/− and FHIT+/+ mice
that were then stressed and examined for diﬀerences in cell
cycle kinetics and survival [30]. The same experiment was
also performed with human FHIT-negative and -positive
cancer cell clones. A larger fraction of FHIT-negative murine
kidney cells survived treatment with mitomycin C or UVC
light compared to FHIT-positive cells. Approximately 10-
fold more colonies of mouse FHIT-deﬁcient cells survived
high UVC doses in clonogenic assays. Compared to wild
type cells, similar results were also obtained with human
cancer cells. After low UVC doses, the rate of DNA synthesis
in mouse FHIT−/− cells decreased more rapidly and steeply
thaninFHIT+/+ cells.UVCsurvivingFHIT−/− cells appeared
transformed and exhibited more than 5-fold increase in
mutation frequency. Such increased mutation burden4 Journal of Biomedicine and Biotechnology
could explain the susceptibility of FHIT-deﬁcient cells to
malignant transformation in vivo [30].
An ionizing radiation study reported that FHIT could
protect human cells from high doses of ionizing radiation-
induced mutations at the HPRT locus [31], suggesting,
once more, the potential protective eﬀect of FHIT in DNA
damage-inducedcarcinogenesis.However,itwasstillunclear
whether FHIT could prevent high dose radiation-induced
carcinogenesis or whether it plays any role in a low-dose
environment. To investigate eﬀects of multiexposure to low
dose radiation at a high dose rate on tumorigenesis and
whether FHIT plays a protective role in the process, Yu et
al. [32] irradiated FHIT+/+ and FHIT−/− mice with 1Gy
× 1o r0 . 1 G y× 10 exposures at a dose rate of 1Gy/min,
sacriﬁced the mice at 1.5 years after radiation and studied
multiorgan tumorigenesis. The results showed that although
the spontaneous tumorigenesis in these mice was relatively
high, 1Gy x1 exposure dramatically increased multiorgan
tumordevelopment and FHIT−/− mice showed more tumors
than FHIT+/+ animals. However, 0.1Gy x 10 exposures did
not increase tumorigenesis, and there was no signiﬁcant
diﬀerence between FHIT+/+ and FHIT−/− mice. Thus, these
results showed that FHIT could prevent high dose radiation-
induced tumor development but has no eﬀect in a low dose
environment [32].
In the last ﬁve years, FHIT-deﬁcient animals were used
to produce mice deﬁcient for multiple tumor suppressors
or upregulated oncogene, and to discover eﬀects due to
the association of loss/reduction of FHIT and simultaneous
deregulation of another cancer gene. Thus far, three articles
havebeenpublishedonthissubject:tworegardingthetumor
suppressor genes Vhl and Nit, and one on the oncogene
HER2 (Figure 1).
Since alterations to the FHIT gene as well as other
suppressor genes mapping to human chromosome 3 play an
important role in development of lung and other cancers,
we decided to determine if FHIT absence, in combination
with deﬁciency of an additional tumor suppressor on
human chromosome 3p, would aﬀect the frequency of
tumor induction. Thus, we examined the spontaneous and
dimethylnitrosamine (DMNs-) induced tumor phenotype
of FHIT−/−Vhl+/− mice [33]. Whereas no spontaneous lung
tumors were observed in FHIT−/− or Vhl+/− mice, 44%
of FHIT−/−Vhl+/− mice developed adenocarcinomas by two
years of age. In addition, DMN induced lung tumors
(adenomasandcarcinomas)in100%ofFHIT−/−Vhl+/− mice
and adenomas in 40% of FHIT−/− mice by the age of 20
months. Thus, double deﬁciency in murine homologues
of human 3p suppressor genes (Figure 1(a)) predisposes to
spontaneous tumor formation and induced lung cancers
recapitulating a pattern of lung cancer development similar
to the human counterpart [33].
Manuela Campiglio’s group had previously shown that
FHIT protein levels could be regulated by FHIT proteasome
degradationmediatedbyEGF-dependentactivationofEGFR
family members, including HER2, whose overexpression is
linked to poor prognosis in breast cancer [34]. To test
for a possible cooperation of the FHIT and HER2 genes,
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Figure 1: Cooperating eﬀect of FHIT with Vhl (a), HER2 (b), and
Nit1 (c) in mouse tumorigenesis.
crossedwithanimalscarryingtheHER2/neuproto-oncogene
driven by the mouse mammary tumor virus promoter [35].
All FHIT heterozygous mice developed mammary tumors,
whereas tumor incidence was reduced by 27% in FHIT
wild type animals, which remained tumor-free at twenty
months. These ﬁndings (Figure 1(b)) suggested a protective
role for FHIT in HER2-driven mammary tumors and point
tocooperationbetweenFHITlossandHER2over-expression
in breast carcinogenesis [35].
Mammalian Nit1 is a member of a large gene family
with some branches conserved from bacteria to mammals;
interest in an association of Nit1 alterations with cancer
development in mammals began with the ﬁnding that in
ﬂies and worms Nit1 is fused to the N-terminus of the
FHIT protein [36]. Conversely, mammalian Nit1 and FHITJournal of Biomedicine and Biotechnology 5
proteins are encoded by genes on diﬀerent chromosomes.
According to the “Rosetta stone” hypothesis, genes fused
in one organism are likely to be involved in the same
signal or metabolic pathways in organisms in which they
map to separate locations [37]. To investigate roles for
Nit1 in FHIT pathways, Semba et al. [38] generated Nit1
knockout mice and observed that these animals are more
susceptible to tumor induction, like FHIT-deﬁcient mice.
Then the authors compared the tumor susceptibility of
FHIT−/− micewiththatofFHIT−/−Nit1−/− doubleknockout
animals after oral delivery of N-nitrosomethylbenzylamine
(NMBA)andobservedthatdoubleknockoutmicedeveloped
signiﬁcantly more spontaneous and NMBA-induced tumors
than FHIT−/− mice [39]. When two distinct cancer genes
are involved in the same pathway, the disruption of both
their activities is not expected to lead to increased tumor
susceptibility relative to the silencing of just one of the
genes. Thus, results of the double knockout experiment
(Figure 1(c)) suggested that FHIT and Nit1 work, at least
to some extent, in diﬀerent pathways and their tumor
suppressor activities are additive [39].
Silvio De Flora’s group, in collaboration with us, was
interested in studying the eﬀect of FHIT-deﬁcient mice after
exposure to cigarette smoke or benzo[a]pyrene (B[a]P), a
prototype of genotoxic and carcinogenic polycyclic aromatic
hydrocarbons (PAHs) that are a fundamental component of
cigarette smoke. In the ﬁrst of these studies, wild type and
FHIT+/− mice were treated with multiple doses of B[a]P by
gavage [40]. All mice, irrespective of their FHIT status, were
sensitive to induction of forestomach tumors, while preneo-
plastic lesions of the uterus were more frequent in FHIT+/−
mice. The ﬁrst generation of the cross between C57BL/6J
and 129/SvJ strains (B6/129 F1) underwent spontaneous
alopecia areata, an inﬂammatory skin disease, and hair bulb
cell apoptosis. This phenotype was greatly accelerated by
FHIT heterozygosity, suggesting that FHIT may play a role
in the pathogenesis of alopecia areata [40]. In a separate
report, D’Agostini et al. [41] exposed wild type and FHIT+/−
rodents to environmental cigarette smoke (ECS). Evaluation
of FHIT expression in the respiratory tract after 14 days of
exposure to ECS revealed unequivocal evidence that FHIT
is an early, critical target in smoke-related carcinogenesis
[41], but heterozygosity for FHIT does not seem to confer an
increased susceptibility of mice in terms of early biomarkers
like apoptosis, cell proliferation, bulky DNA adducts in the
lung, and various cytogenetical damages [42].
To determine if a nonfragile, cDNA version of a FHIT
allele, expressed from a chromosomal region outside the
fragilesite,couldreducesusceptibilityofmicetocarcinogen-
induced tumorigenicity, we generated FHIT transgenic mice
on a FHIT+/+ and FHIT+/− background, treated them with
NMBA,andassessedtheirtumorburdenrelativetowildtype
andFHIT+/− mice[43]. The tumor burden in NMBA-treated
male transgenic mice was signiﬁcantly reduced, suggesting
that indeed a nonfragile FHIT protein could protect from
tumorigenesis, while female transgenic animals were not
protected. To determine if the diﬀerence in protection
could be due to diﬀerences in epigenetic changes at the
transgene locus in male versus female mice, we examined
expression, hypermethylation and induced re-expression of
FHIT transgenes in males and females or cells derived from
them. The diﬀerences detected in the epigenome did not
explain the diﬀerences in protection between the two sexes
[43] but this should be reexamined with more sensitive
epigenome sequencing methods now available.
FRA3B, the most active or most fragile of the human
common fragile sites, is frequently altered in environmental
carcinogen-associated cancers and in hematopoietic disor-
ders [23, 44]. We reported that absence of FHIT in mouse
hematopoietic cells exposed to hydroquinone, a genotoxic
benzene metabolite, led to resistance to induction of cell
death in vitro and escape from bone marrow suppression
in transplanted mice [45]. Immunohistochemical analy-
ses of transplanted hydroquinone-exposed, FHIT−/−,a n d
FHIT+/+ bone marrow revealed absence of apoptosis and
senescence markers in KO bone marrow. Accordingly, the
long-term survival of hydroquinone-exposed FHIT-deﬁcient
bone marrow-transplanted mice allowed accumulation of
inaccurately repaired DNA lesions and premalignant alter-
ations in bone marrow-derived cells, suggesting that FHIT
deﬁciency leads to unscheduled survival of genotoxin-
exposed bone marrow cells, and increases the population of
stem or precursor cells with damaged genomes and resultant
accumulation of genomic alterations [45].
Since the FHIT gene is altered in human bladder cancer
[46], Raﬀaele Baﬀa’s laboratory published a report on a
chemically induced urinary bladder cancer model in FHIT-
deﬁcient mice [47]. Recently, they used the same model to
investigate the chemopreventive role of a COX-2 inhibitor,
rofecoxib, in the development of bladder cancer in FHIT+/+,
FHIT+/−,a n dFHIT−/− mice [48]. Though the COX-2
inhibitor decreased the incidence of neoplastic lesions in all
three genotypes, the authors conﬁrmed that FHIT-deﬁcient
mice are highly susceptible to N-butyl-N-(-4-hydroxybutyl)-
nitrosamine (BBN), providing an in vivo model suitable for
bladder cancer preclinical studies [48].
3. Wwox
Since WWOX is down-regulated in most human cancers
and shows tumor suppressor function in diﬀerent cell lines,
Wwox knockout mice may be a useful tool to study the
t u m o rs u p p r e s s o ra c t i v i t yo fW w o x[ 25]. The mouse Wwox
gene is similar to its human homologue, it spans the CFS
Fra8E1 [49], and its expression induces apoptosis in murine
cell lines [50]. Consequently, the murine Wwox gene is an
appropriate model for studying the anti-tumor function of
the human WWOX gene [25]. Thus, in 2007, we developed
a mouse strain lacking Wwox expression [51]. The resulting
single- and double-allelic targeted ablations exhibiting two
completely diﬀerent phenotypes.
Heterozygous mice developed normally and allowed
to assess how the inactivation of a single Wwox allele
spontaneously contributes to tumorigenesis [51]. Thus, after
monitoring Wwox+/+ and Wwox+/− littermates for two years,
we observed that the incidence of tumor formation in
Wwox+/− mice was signiﬁcantly higher than in wild type
animals and included lung and mammary tumors [51].6 Journal of Biomedicine and Biotechnology
Noteworthy was the fact that in some tumors the second
Wwox allele remained intact, suggesting haploinsuﬃciency
for tumor suppression. To evaluate the role of WWOX
in tumor progression, Wwox+/+ and Wwox+/− animals
were then treated with diﬀerent chemical carcinogens and
the incidence of tumor formation was examined. In one
study, we utilized the chemical mutagen ethyl-nitroso-urea
(ENU) and forty weeks after its administration, incidence
of tumor formation in Wwox+/− mice was 80% compared
to 40% in Wwox+/+ animals. The tumor spectrum included
leukemia and lung, mammary, and liver tumors [51]. In
another study [52], wild type and Wwox+/− mice were
treated with the gastric carcinogen NMBA. Fifteen weeks
after its administration, almost 100% of Wwox+/−mice
had developed forestomach tumors ranging from adeno-
mas to invasive carcinomas, whereas tumors were present
only in 29% of Wwox+/+ animals. Interestingly, Wwox+/−
forestomachs showed moderately strong staining of Wwox
protein in the near normal epithelium but weak and diﬀuse
staining in the carcinoma areas of the same sections, thus
conﬁrming the haploinsuﬃcient feature of Wwox [52].
Another report provided further support for the in vivo
tumor suppressor activity of Wwox [53]. These authors
produced a hypomorphic strain of mice with very low levels
of Wwox protein. Wwox h y p o m o r p h i cm i c ew e r ev i a b l eb u t
with a signiﬁcantly shorter lifespan in comparison to wild
type animals and females exhibited a higher incidence of
spontaneous lymphomas [53].
Wwox−/− mice are born with no obvious malformations
[51, 54]. Nevertheless, these mice exhibit a metabolic
disorder characterized by hypoglycemia and hypocalcaemia
and die at 3-4 weeks of age, showing growth delay, and
an impaired ratio of organ/body mass in several tissues
including spleen, thymus, and brain. Though smaller in
size, they did not display abnormal behavior or impaired
motor skills [54]. These and other features of the Wwox
homozygous phenotype support multiple and unique roles
of Wwox in a number of biological activities, like lipid
metabolism and steroidogenesis [25], that are beyond the
scope of this paper.
Although Wwox−/− mice died very prematurely, by the
age of three weeks they develop focal lesions along the
diaphysis of their femurs resembling early osteosarcomas
[51]. Osteosarcoma derives from proliferation of undiﬀer-
entiated osteoblasts. Intriguingly, we observed an impaired
diﬀerentiation in Wwox−/− osteoblasts, suggesting a possible
relationship between these two observations. Wwox, in
fact, seems to be essential in regulating proliferation and
maturation of osteoprogenitor cells during bone formation
[54]. We observed an increase in Runx2 levels, the master
transcription factor speciﬁc for osteoblast diﬀerentiation, in
femur bones of Wwox−/− mice. In biochemical terms, we
havedemonstratedaphysicalinteractionbetweenWwoxand
Runx2 using co-immunoprecipitation assays [54]. This asso-
ciation suppressesRunx2 transactivationfunction, therefore,
sinceRUNX2autoregulatesitsexpression[55],wespeculated
that absence of Wwox stimulates Runx2 transactivation
function and hence upregulates its expression. Further
investigations are however necessary to gain more insights
into the functional role of the Wwox-Runx2 interactions in
osteosarcoma [25]. Recent results in human osteosarcoma
specimensandcelllinesconﬁrmedthatattenuationofWwox
is associated with increased tumorigenicity and aberrant
expression of Runx2 [56] according to the predictions of
Wwox mouse model.
Since Wwox−/− mice generated using conventional tech-
niquesdieveryearlyinlife,conditionalWwoxknockoutmice
were generated to study the WWOX function in both normal
and cancer tissues [57]. This new model will greatly facilitate
the functional analysis of Wwox in adult mice and will allow
more reﬁned investigations of neoplastic transformation in
speciﬁc target tissues [57]. Other similar Wwox models are
currently in construction as well.
4.Others
Parkin(PARK2)onFRA6E(6q26)isawidelyexpressedubiq-
uitin E3 ligase that is thought to target speciﬁc proteins for
proteasomal degradation, and its mutations are responsible
for autosomal recessive juvenile Parkinson disease [58, 59].
Moreover, diminished or total loss of Parkin expression has
been observed in primary tumors and cell lines derived from
ovarian, liver and lung carcinomas [60, 61], whereas its
restored expression reduced in vivo tumorigenesis in nude
mice [62]. Three Park2 deﬁcient mice have been generated,
but only two models had an abnormal phenotype [63, 64].
Targeted exon3 null mice did not show any degeneration of
dopaminergic neurons of substantia nigra, the neuropatho-
logical hallmark of Parkinson disease, but demonstrated
motor and cognitive defects that resembled the very early
symptoms of patients, prior to the development of overt
clinical symptoms. Null mice did not develop any tumor or
preneoplasticlesion,butinterbreedingofPark2 heterozygous
mice with Apc (min) mice resulted in a dramatic acceleration
of intestinal adenoma development and increased polyp
multiplicity [65].
Deletions at chromosome 7q have been reported in a
variety of human neoplasias: leukemia [66], breast [67],
ovary [68], colon [69], prostate [70], gastric [71], head and
neck [72], pancreatic [73], and renal cell carcinomas [74].
FRA7G (7q31.2) harbors two putative tumor suppressor
genes: CAVEOLIN-1 (CAV-1) and TESTIN (TES).
Caveolin proteins are expressed by caveolae, specialized
invaginations of the plasma membrane that function to
regulate signal transduction within the cell. Cav-1 knockout
mice showed a remarkable lack of caveolae in all nonmuscle
tissuesandareviableandfertile[75–78].Inmice,theabsence
of Cav-1 protein is associated to the reduction of Cav-2
expression, without any change at the transcription level.
Cav-1 null mice did not spontaneously develop tumors,
although Capozza et al. [79] showed that the skin of Cav-
1−/− mice is more susceptible to chemical carcinogenic
(7,12-dimethylbenzanthracene, DMBA) treatment, resulting
in the formation of epidermally derived tumors that are
associated with cyclin D1 up-regulation and ERK1/2 hyper-
activation. Young virgin Cav-1 null mice developed a hyper-
plastic ductal epithelium [80] and complete loss of Cav-1
accelerated the appearance of mammary dysplastic lesions inJournal of Biomedicine and Biotechnology 7
polyoma middle T tumor prone transgenic mice (MMTV-
PyMT) [81]. Loss of caveolin-1 gene expression accelerates
the development of dysplastic mammary lesions in tumor-
prone transgenic mice. These ﬁndings were enforced by
a study demonstrating that CAV-1 haploinsuﬃciency is
suﬃcient to induce the partial transformation of human
breast epithelial cells [82].
However, Cav-1 does not behave as a tumor suppressor
in all cellular contexts. Genetic ablation of Cav-1 in TRAMP
mice decreased the incidence of prostate tumors at 28 weeks
and reduced metastasis to regional lymph-nodes and distant
organs [83]. An increased expression of CAV-1 has been
observed in metastatic lesions and metastasis-derived cell
lines, as compared to primary tumors and primary tumor-
derived cell lines respectively [84]. In summary, CAV-1 is
down-regulated in ovarian, lung and mammary carcinomas,
as well as mesenchymal sarcoma, while it is up-regulated in
prostate, bladder, esophageal and thyroid carcinomas, with
some exceptions.
TESTIN (TES) is a cytoskeleton-associated protein that
localizes along actin stress ﬁbers, at cell-cell contact areas,
and at focal adhesion plaques, where it directly interacts
with Mena [85]. Loss of Tes expression has been observed
in several tumor-derived cell lines [86] while its restored
expression reduced in vivo tumorigenesis in nude mice [87].
Moreover, Tes overexpression enhanced cell spreading and
decreased cell motility [88].
Tes knockout mice were viable and fertile, reproducing at
mendelianratio,anddidnotshowanincreasedrateoftumor
incidence compared to control littermates [89]. Tes null
mice developed NMBA-induced gastric tumors after a zinc
suﬃcient or deﬁcient diet. Interestingly, Tes heterozygous
and homozygous mice developed tumors, independently
from the diet, at the same rate.
Recently, Ma et al. [90], showed that TES is down-
regulated in primary gastric cancer tissues and its expression
level correlates with prognosis: patients with a loss of
expression of TES had a shorter life span than those with an
expressing tumor. The same prognostic correlation has been
also found for head and neck squamous carcinomas [91].
5. Conclusions
A number of knock-out and transgenic mouse models have
been generated to study the in vivo functions of tumor
suppressor genes mapping on CFSs: some of them presented
a phenotype associated with pathophysiological abnormal-
ities, whereas most of them, because of their embryonic
lethality, showed developmental defects. In both instances,
the absence of prezneoplastic or malignant proliferation in
mouse models does not exclude their role in human cancer.
The future in this ﬁeld of investigation probably rests
in the creation of compound mice in which two or more
engineered CFSs tumor suppressors are combined together
to represent more closely human conditions in which
multiple CFSs are often involved at the same time [92].
For example, since sequence fragility usually makes CFS
particularly sensitive to environmental genotoxins, we can
ask what might be the outcome of exposing a potential
FHIT−/−Wwox+/− mouse to such chemical insults when
compared to single knockout animals. This approach could
be even more informative in cases like Tes−/− mice, where
a spontaneous cancer phenotype was not reported and the
combination with other CFS models could reveal complex
aspects of the malignant disease that no single CFS gene can
cause alone.
Recently, it has been determined that, on average, fragile
sites are denser than other genomic regions not only in
protein coding genes but in microRNAs as well [93]. Since
the number of microRNA engineered mouse models of
cancer is increasing by the month [94, 95], it is likely that
future modeling of human neoplasia will be greatly reﬁned
when CFS models include alterations of coding and non-
coding genes alike.
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